leisure time -WSS

leisure time

author：comprehensive 2025-09-27 12:58:33 - browse：3

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The lessons of Aduhelm, an Alzheimer's drug that was not to be

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

Listen: Who gets the credit for GLP

Vertigo drug brings hope for rare neuron disorder, Niemann

Juul spent big to court Black leaders to promote its e

Time to name cancers by genetics, not organ of origin, expert says

Paxlovid should be available without a positive Covid test

focus

leisure time

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

New Ultima Genomics DNA sequencer can read genome for $100

Sports medicine is finally prioritizing gender equality

How one patient went off dialysis — and others can too

Wildfire smoke exposes gaps in outdoor worker protections

Medicare drug price negotiation’s day in court

Moonlake's readout produced a cash windfall. Risks remain

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Medical leaders decry Supreme Court decision on affirmative action

Mindstrong's demise and the future of mental health care

Wikipedia

ARCH Venture Partners is raising $3 billion for a life sciences fund

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Biogen shutters digital health group, ends Apple study, in cost cutting move

How one patient went off dialysis — and others can too

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

FDA advisers vote against ALS treatment from BrainStorm

leisure time

Wikipedia

leisure time

entertainment